Colistin + levofloxacin group (n = 120) | Meropenem + levofloxacin group (n = 112) | p value | |
---|---|---|---|
Age, years (n = 232) | 63 [49–71] | 60.5 [50–70] | 0.370 |
Female (n = 232) | 28 (23.3) | 31 (27.7) | 0.448 |
Underlying diseases (n = 232) | 41 (34.2) | 38 (33.9) | 0.969 |
Diabetes mellitus | 19 (15.8) | 22 (19.6) | 0.447 |
Chronic liver disease | 6 (5.0) | 5 (4.5) | 0.848 |
Congestive heart failure | 2 (1.7) | 2 (1.8) | 0.945 |
Chronic renal disease | 1 (0.8) | 4 (3.6) | 0.151 |
Chronic obstructive pulmonary disease | 21 (17.5) | 10 (8.9) | 0.055 |
Neoplasia | 5 (4.2) | 3 (2.7) | 0.535 |
Infection characteristics (n = 232) | |||
Days from MV to VAP | 8 [6–11] | 7.5 [6–11] | 0.844 |
Clinical presentation | |||
Sepsis | 67 (55.8) | 62 (55.4) | 0.992 |
Severe sepsis | 27 (22.5) | 26 (23.2) | |
Septic shock | 26 (21.7) | 24 (21.4) | |
APACHE II trial inclusion—VAP diagnosis | 19 [14–24] | 17 [13–22] | 0.065 |
APACHE II ≤ 15 | 40 (33.3) | 46 (41.1) | 0.223 |
APACHE II > 15 | 80 (66.7) | 66 (58.9) | |
Multilobar infiltrates (Rx film) | 69 (57.5) | 54 (48.2) | 0.157 |
Baseline CPIS | 6 [4–7] | 5 [4–7] | 0.662 |
Baseline creatinine clearance (mg/h) (n = 231) | 101.0 [70.9–131.0] | 113.0 [66.8–163.4] | 0.424 |
Microbiological diagnosis (n = 157) | 82 (52.2) | 75 (47.8) | 0.824 |
VAP caused by A. baumannii, P. aeruginosa, and K. pneumoniae (n = 79) | 40 (48.8) | 39 (52) | 0.811 |
MIC distribution | |||
Meropenem MIC | |||
≤ 2 mg/l—susceptible | 16 (40) | 18 (46.2) | 0.719 |
> 2–8 mg/l—intermediate | 4 (10) | 5 (12.8) | |
> 8 mg/l—resistant1 | 20 (50) | 16 (41) | |
Colistin MIC | |||
≤ 2 mg/l—susceptible2 | 35 (87.5) | 32 (82.1) | 0.500 |
> 2 mg/l—resistant | 5 (12.5) | 7 (17.9) | |
Levofloxacin MIC | |||
≤ 2 mg/l—susceptible | 16 (40) | 17 (43.6) | 0.746 |
> 2 mg/l—resistant | 24 (60) | 22 (56.4) | |
Bacteremia (n = 232) | 21 (17.5) | 17 (15.2) | 0.633 |
Treatment (n = 232) | |||
Empirical treatment with vancomycin | 19 (15.8) | 19 (17) | 0.816 |
Empirical treatment with linezolid | 17 (14.8) | 18 (16.4) | 0.744 |
Appropriate empirical antibiotic treatment (n = 157) | 65 (79.3) | 54 (72) | 0.288 |
Duration of antibiotic treatment | |||
Days of treatment (n = 232) | 9 [5–14] | 7.9 [5–11] | 0.035 |
Days of levofloxacin (n = 232) | 8 [5–13] | 7 [4–9] | 0.003 |